Facebook
Britain's News Portal
Around The Clock
BREAKING
Loading latest headlines…

Ellipses Pharma plans London Stock Exchange listing targeting £450m valuation

Ellipses Pharma, a cancer drug venture, is reportedly planning to list on the London Stock Exchange through a reverse takeover, aiming for a valuation between £450m and £500m.

  • Ellipses Pharma is a clinical-stage oncology venture founded by Sir Chris Evans.
  • The company's investors include celebrity figures and Abu Dhabi's sovereign wealth fund, which holds a 45% stake.
  • Ellipses plans to list in London as soon as February via a reverse takeover of Wolfram Resources.

Ellipses Pharma, a cancer drug venture, is reportedly preparing to list on the London Stock Exchange. The clinical-stage oncology company, founded by British biotech entrepreneur Sir Chris Evans, is targeting a listing valuation of between £450m and £500m.

The venture's investors include Sir Chris Evans, housebuilder founder Steve Morgan, and Sir Tom Hunter’s West Coast Capital. Comedian Jimmy Carr and Andrew Lloyd Webber are also among the celebrity investors. Abu Dhabi’s sovereign wealth fund is the single largest investor, holding a 45% stake.

Ellipses is planning a London listing as soon as February through a reverse takeover of Wolfram Resources. This move follows earlier considerations of listing on the Nasdaq or in Hong Kong in 2025. Berenberg is reported to be assisting with the deal, and Ellipses is also preparing to appoint non-executives to its board.

Why this matters: A successful listing could provide a boost to London's biotech and pharmaceutical sector, which has seen companies consider opportunities in America.

Related Articles

Get the news that matters.

Join thousands of readers getting the best of British news straight to their inbox.